<DOC>
	<DOCNO>NCT01726946</DOCNO>
	<brief_summary>A Phase 2 study evaluate safety efficacy two different daily dose VX-135 combination ribavirin treatment-naïve subject chronic hepatitis C</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Safety Efficacy VX-135 With Ribavirin Treatment-Naïve Subjects With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Key Subjects ( male female ) must age 18 60 year screen Subjects must genotype 1 Chronic Hepatitis C Subjects must treatment naïve Subjects must laboratory value screen within limit specify protocol Key Evidence cirrhosis Female subject pregnant nurse male subject female partner childbearing potential unwilling adhere contraception requirement , pregnant nursing , plan become pregnant study Any cause significant liver disease addition hepatitis C Human immunodeficiency virus 1 2 Diagnosis suspect hepatocellular carcinoma History organ transplant , exception corneal transplant skin graft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>CHC</keyword>
</DOC>